PMID

Data

Article Title

Organization

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

Merck

Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.

Pfizer

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.

Pfizer

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Pfizer

Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.

Chinese Academy of Sciences

Glucokinase-activating ureas.

Osi Pharmaceuticals